

## Healthcare on the Hill

December 5, 2006

Please join the Washington Policy Analysis and Healthcare Research teams December 5<sup>th</sup> at the Hyatt Regency Capitol Hill for our Healthcare on the Hill conference 8:00 am until 4:00 pm Space is limited, so contact your FBR sales representative for further details.

In the healthcare services arena, we will explore critical healthcare policy proposals related to directly negotiating pricing with drug companies, "filling in" the Part D donut hole, changing reimbursement levels to Medicare Advantage and private fee for service providers, and the future of the PPO stabilization fund. In addition, we expect to identify precarious healthcare segments—ranging from oxygen providers, durable medical equipment manufacturers, and specialty hospitals—subject to cuts in the lame duck budget negotiations.

On the drug and biotech side, we will assess the chances of drug reimportation legislation, determine the future efforts to address drug safety, regulate authorized generics, and the follow-on attachments to the PDUFA reauthorization.

Investors can expect to see representatives from CMS, the FDA, the White House, House Speaker Pelosi's office, congressional committee staffers, and various trade associations representing pharmaceuticals and biotechnology, managed care, hospitals, and the medical device industry.

Featured Speakers

Congressman Pete Stark, Anticipated Chairman of the House Ways & Means Health Subcommittee Congressman Henry Waxman, Anticipated Chairman of the House Government Reform Committee Congressman Bill Thomas, Chairman of the House Ways & Means Committee Senator Jack Reed, Member of the Senate Health, Education, Labor & Pensions Committee Carol Kelly, Policy Director at the Center for Medicare & Medicaid Services Wendell Primus, Health Policy Advisor to Anticipated Speaker Nancy Pelosi Amy Hall, Energy and Commerce Committee Legislative Aide Charles Clapton, Health Policy Advisor to Speaker Hastert Howard Cohen, Consultant for Healthcare Associates Steve Ubl, President & CEO of AdvaMED Food and Drug Administration Representative (*Invited*) White House Representative (*Invited*) America's Health Insurance Plans Representative (*Invited*) Pharmaceutical Research and Manufacturers of America Representative (*Invited*)